Ilsung Pharmaceuticals Co., Ltd.

KSE 003120.KS

Ilsung Pharmaceuticals Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2023: USD 1.19 M

Ilsung Pharmaceuticals Co., Ltd. Total Non-Current Liabilities is USD 1.19 M for the year ending December 31, 2023, a -76.15% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Ilsung Pharmaceuticals Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 4.97 M, a 25.19% change year over year.
Ilsung Pharmaceuticals Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 3.97 M, a -37.51% change year over year.
Ilsung Pharmaceuticals Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 6.36 M, a 29.13% change year over year.
Ilsung Pharmaceuticals Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 4.92 M, a -21.62% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

KSE: 003120.KS

Ilsung Pharmaceuticals Co., Ltd.

CEO	Mr. Seok-geun Yoon
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	84-gil 9, Wonhyo-ro
Employees	224
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Plastics

Description

Ilsung Pharmaceuticals Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, anti-coagulants, circulatory system drugs, contrast agents, diabetes treatments, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, anesthetics, antipyretics, and cardiovascular system products. Ilsung Pharmaceuticals Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years